GSK has filed for marketing approval with the EMA for its triple combination therapy to treat chronic obstructive pulmonary disease.

The submission is based on results from a Phase 3 trial of the triple combo therapy. That study found that the candidate significantly reduced the worsening of COPD symptoms, like shortness of breath and phlegm accumulation, compared to standard once-daily treatments.

Last month, GSK submitted an NDA for its COPD candidate that combines the company’s Relvar/Breo Ellipta and Anoro Ellipta.